Scalper1 News
Sarepta Therapeutics (SRPT) stock jumped more than 50% in early trading Wednesday, to an eight-month high, after the company said late Tuesday that the FDA had finally agreed to a refiling plan for its Duchenne muscular dystrophy (DMD) drug eteplirsen. Sarepta said the FDA agreed to a rolling submission plan, with the first batch of data delivered this week and the rest by midyear. That’s in line with previous company guidance, but investors had Scalper1 News
Scalper1 News